Does Diabetes Affect Sex Drive? What 50 Studies of 9,532 Women Found
Share
Does diabetes affect sex drive? Yes, and the pooled numbers are large: across 50 studies covering 9,532 women with diabetes, 53% scored in the range questionnaires call sexual dysfunction (95% CI 46% to 61%). The more useful half of that analysis is what came out associated with it. Depression carried the highest odds at 2.781, diabetic neuropathy 2.550, and diabetic complications 2.258, with age and longer diabetes duration also raising the odds. Blood sugar control appears once in this literature, in a review of Indonesian studies where HbA1c correlated with the desire section of the questionnaire and nothing else on it. So the diagnosis on your chart is a context for what happened to your desire. It is a long way from a verdict on it.
- Across 50 studies and 9,532 women with diabetes, 53% scored in the dysfunction range on a standard questionnaire (95% CI 46% to 61%).
- In that same analysis, depression was the factor most strongly associated with it (OR 2.781, 95% CI 2.012 to 3.844), ahead of diabetic neuropathy (OR 2.550, 95% CI 1.755 to 3.707) and diabetic complications (OR 2.258, 95% CI 1.346 to 3.788). Age and longer diabetes duration also raised the odds.
- A separate pooling of 16 studies from 9 countries (N = 3,261) put diabetic women below non-diabetic controls at SMD -0.764 (95% CI -1.042 to -0.486). Heterogeneity in that analysis was 91.65% and the 95% prediction interval ran from -1.853 to 0.325, crossing zero. Individual women vary enormously.
- Type 1 shows the same shape: 38.5% in one review and 37% in another, with depression and diabetes duration the predictors that keep reappearing.
- Blood sugar control shows up once, in an Indonesian sample of 572 women, where HbA1c correlated with the desire section of the questionnaire alone. Antihypertensive use and being over 45 or menopausal were the other associations in that review.
Figures from Wang et al. 2026 (PMID 41999390) and Tandogan 2026 (PMID 42299862). Both are pooled observational data, so every figure here is an association.
"Is it the diabetes, or is it me?"
Type the question into a search bar and a confident answer comes back: diabetes kills libido, here is the protocol that fixes it. The research is quieter and more specific. Something did change, it is measurable, and most of what carries it has a name of its own.
Two meta-analyses published this year set the shape. One pooled 50 studies of women living with diabetes and asked what travels with lower scores. The other compared diabetic women against non-diabetic controls and got a medium-to-large gap with an honest warning attached. Together they say the same thing twice: the association is real at the group level, and its size in any one woman is anybody's guess.
This is the fifth time we have walked into this shape of question, after the thyroid and low libido connection, PCOS and low sex drive, endometriosis and low sex drive, and autoimmune disease and low sex drive. A diagnosis arrives, it explains a real part of what you are feeling, and then it gets stretched to cover everything. The stretch is comforting, because one cause you cannot change is easier to hold than five smaller ones you can. It is also where the harm sits: once the diagnosis owns the whole experience, the parts that respond to attention stop getting any. Our wider guide on why your libido is so low walks through those other parts.
What 50 studies of 9,532 women found
Wang and colleagues searched three databases for twenty years of literature on sexual health in women with diabetes and pooled what they found. Fifty articles met the criteria, covering 9,532 women. The pooled prevalence of scoring in the dysfunction range came out at 53%, with a 95% confidence interval from 46% to 61%.
That figure alone is easy to misread. It describes a questionnaire threshold in a pooled group of women mostly recruited in clinics, and clinic samples skew toward women whose diabetes is being actively managed for a reason. The second half of the paper is the part worth reading, where the authors report which factors came out associated with the score.
Depression led, at odds of 2.781 (95% CI 2.012 to 3.844). Diabetic neuropathy followed at 2.550 (95% CI 1.755 to 3.707), and diabetic complications generally at 2.258 (95% CI 1.346 to 3.788). Age and longer diabetes duration also raised the odds. Every one of those is an observed association in cross-sectional data, so none of them proves a direction of travel. They still point somewhere specific, and it is not the word "diabetes" doing the work on its own.
The three factors most strongly associated with lower scores
Odds ratios from one paper, Wang et al. 2026. Bars run from 1.0, which is the point of no association. Orange whiskers are the 95% confidence interval.
Source: Wang H et al., The Journal of Sexual Medicine 2026 (PMID 41999390). 50 articles, 9,532 women. Cross-sectional pooled data, so these are associations and no direction of cause can be read off them.
Depression sitting at the top is the finding worth carrying around, because depression flattens desire in women who have never had a blood sugar reading taken. We wrote about it on its own terms in depression and low libido. Neuropathy and complications are the other two, and an endocrinologist already tracks both.
Lower than women without diabetes, and shakier than it looks
The comparison most people want is diabetic women against women without diabetes. Tandogan pooled 16 studies from 9 countries, N = 3,261, and found diabetic women scoring lower, at a standardized mean difference of -0.764 (95% CI -1.042 to -0.486). The author calls that a medium-to-large effect, and it is.
The same abstract publishes the reason to hold it loosely. Heterogeneity across those 16 studies was 91.65%, about as high as meta-analysis gets, and the 95% prediction interval ran from -1.853 to 0.325. A prediction interval says where a new study would be expected to land. This one crosses zero, so the next study of diabetic women and controls could plausibly find a large gap or none at all. The author's own conclusion says the heterogeneity and that interval warrant cautious interpretation.
Two subgroup results are worth knowing and neither is a verdict. The effect was numerically larger in type 1 (SMD -0.994) than in type 2 (SMD -0.627), though the subgroup difference did not reach significance (p = .498). Menopausal status did moderate it (p = .043), with premenopausal samples at -0.911 and mixed-status samples at -0.434.
The honest version: women with diabetes score lower on average, that average sits on unstable ground, and the spread between women is wide enough that the group number tells you little about your own evening.
| Paper and population | Size | Headline figure | What carried it, and how certain |
|---|---|---|---|
| Wang 2026, women with diabetes | 50 studies, 9,532 women | 53% in the dysfunction range (95% CI 46% to 61%) | Depression 2.781, neuropathy 2.550, complications 2.258. The largest pool here, and every figure is an association |
| Tandogan 2026, diabetic women against non-diabetic controls | 16 studies, N = 3,261, 9 countries | SMD -0.764 (95% CI -1.042 to -0.486) | Fragile. Heterogeneity 91.65% and a prediction interval of -1.853 to 0.325 that crosses zero |
| Zhang 2023, type 1 | Pooled prevalence review | 38.5% (95% CI 32.1% to 45.0%); odds against healthy controls 3.77 (2.24 to 6.35) | Depression 2.77 (1.29 to 5.93) and longer duration 1.19 (1.06 to 1.34). The authors flag significant heterogeneity |
| Banerjee 2026, type 1 | 18 studies, N = 2,476 | 37% (95% CI 30% to 43%) | Adjusted risk ratio 2.10 (1.30 to 3.39) against age-matched controls. Depression and diabetes-control indicators the most consistent predictors; pump use protective |
| Hashim 2023, premenopausal type 1 | 8 studies | Odds three times higher, 3.8 (95% CI 1.8 to 8.0) | A wide interval on a small pool. Depression, anxiety and duration named as associated factors |
| Pasaribu 2023, type 2 in Indonesia | 10 studies, 572 women | 52% (95% CI 49% to 56%) | Age over 45 or menopause and antihypertensive use associated. HbA1c correlated with the desire section alone. One country |
| Maghalian 2024, gestational diabetes | 6 studies | Total score SMD -1.80 (95% CI -3.44 to -0.15) | The authors grade this evidence low certainty and ask for larger samples |
"My numbers are fine and I still feel flat"
This is the reader the literature serves worst. A1C in range, the endocrinologist pleased, and desire still nowhere to be found. If blood sugar were the whole story, the story would have ended when the numbers came back.
Only one review in this set went looking for blood sugar directly, and what it found is narrow. Pasaribu and colleagues pooled 10 Indonesian studies of 572 women with type 2 diabetes and reported HbA1c correlating with the desire section of the questionnaire and with nothing else on it. That is a single-country pool of moderate size, so treat it as a lead worth following. Control has some connection to wanting, and it is narrow enough to leave most of the experience unexplained.
The same review named two other associations: being over 45 or menopausal, and the use of antihypertensive medication. The second one is worth a hard look, because blood-pressure medicines are common in diabetes care and several classes are documented desire suppressants in their own right. We laid that out in blood pressure medication and sex drive. Nobody should stop or change a prescription over a blog post, and the review is a good reason to ask your doctor to walk the list with you.
Then there is the tired-all-the-time bundle: low energy, foggy head, no appetite for anything after 8pm. Sleep sits underneath it, and untreated sleep apnea travels with type 2 diabetes often enough to be worth one question at your next appointment. We covered both in sleep apnea and low libido and brain fog and sex drive. If your labs came back unremarkable and you were sent home with nothing to work on, normal labs, low libido is the guide for that exact position.
Type 1, and diabetes that arrives in pregnancy
Three reviews cover type 1 and they land close together. Zhang and colleagues pooled a prevalence of 38.5% (95% CI 32.1% to 45.0%) with odds against healthy controls of 3.77 (95% CI 2.24 to 6.35), and named two predictors: depression at 2.77 (95% CI 1.29 to 5.93) and longer diabetes duration at 1.19 (95% CI 1.06 to 1.34). Banerjee and colleagues pooled 18 studies covering 2,476 women and got 37% (95% CI 30% to 43%), with an adjusted risk ratio against age-matched controls of 2.10 (95% CI 1.30 to 3.39). Their most consistent predictors were depression and diabetes-control indicators, and continuous insulin infusion by pump came out protective.
Hashim and colleagues, looking only at premenopausal women with type 1 across eight studies, put the odds three times higher than in women without diabetes, at 3.8 with a 95% confidence interval from 1.8 to 8.0. That interval is wide, which is what a small pool looks like when it is reported honestly. Depression, anxiety and duration were again the associated factors.
Two of the three name depression first, in a population whose metabolic story is nothing like type 2. That repetition across diabetes types is the strongest signal in this literature.
Diabetes that arrives in pregnancy has one meta-analysis behind it. Maghalian and Mirghafourvand pooled six studies and found lower total scores in women with gestational diabetes than in controls, at SMD -1.80 (95% CI -3.44 to -0.15). The authors grade that evidence low certainty and ask for larger samples, which is the right way to read a six-study pool with an interval that wide.
What about men
The men's literature asks a different question. Vasquez-Tirado and colleagues pooled 22 studies covering 43,038 adult men and found low total testosterone associated with a higher risk of newly diagnosed type 2 diabetes, at odds of 1.52 (95% CI 1.10 to 2.10), with heterogeneity of 79%. The arrow there runs from the hormone to the diagnosis, close to the reverse of how the subject usually gets discussed.
In practice, low desire and a new diabetes diagnosis in the same year are worth mentioning together at one appointment. Testosterone is a blood test and a doctor's conversation, and any decision that follows is a prescription decision. NUUD has no place in it. We have written the general version in low libido in men, and the specific question of what hormone therapy does and does not deliver in does TRT fix low libido.
What to take to your doctor
Six things this literature says are worth raising
The largest association in the biggest pool, at 2.781, and it repeats across type 1 and type 2.
One review found control correlating with the desire section of the questionnaire. Bring the trend.
Neuropathy came out at 2.550 and complications at 2.258. Both are already on your screening list.
Blood-pressure drugs especially. Antihypertensive use was an association in the Indonesian review.
Untreated sleep apnea is common in type 2 and flattens energy and desire together.
Type 1 is autoimmune, and autoimmune conditions travel in company. Ask when yours was last checked.
Built from PMID 41999390, 37898063, 37548250 and 42209931. Every item is a question for a clinician who knows your history.
Take it into the room in this order, since the appointment will be shorter than you want:
- Say it out loud first. Desire is the item most likely to get skipped if it waits for the last two minutes.
- Ask for mood in the same visit. It is the largest association in the largest pool, treatable on its own terms, and the one item here with nothing to do with your pancreas.
- Bring the A1C trend line. Control showed a narrow connection to desire in one review, so it belongs in the conversation without owning the whole explanation.
- Hand over the complete medication list, blood-pressure drugs included, so somebody qualified reads it with this question in mind. Change nothing on your own.
- Mention nerve symptoms, even small ones: tingling, numbness, feet gone quiet. Neuropathy carried odds of 2.550 in the biggest analysis here.
- Answer the sleep question honestly, snoring included. Ask about thyroid too if your diabetes is type 1.
The everyday levers, and where a botanical fits
Before anything else here: a large share of people living with diabetes also take blood-pressure medication or carry a cardiovascular or kidney condition. NUUD's own label says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For many readers of this article, that sentence is the answer. Talk to your doctor first and bring the label.
Separate from anything clinical, a few ordinary things move desire in most people, and the free ones do more work than the internet admits.
- Care for your mood, taken as seriously as your blood sugar. It is the biggest association in this literature.
- Sleep, in quantity and quality, with the apnea question asked and answered.
- Movement you actually enjoy, which does its own separate work. Exercise and libido covers that evidence.
- Weight, if it is on your list with your doctor, is its own lever with its own evidence and its own disappointments, covered in why weight loss did not fix your libido and GLP-1 medication and libido.
- Time and safety, with a partner or on your own, with no expectation attached to it.
- A botanical supplement, if you want one, as the smallest lever on the list.
NUUD is a botanical supplement built around desire in general. It does nothing for blood sugar, nothing for nerves, nothing for mood, and it has no role in managing a medical condition of any kind. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If your doctor has looked at the label and has no objection, and you want one more small thing on the desire side, that is what our women's libido gummies are for. There is a men's version of the same formula.
"Nothing is wrong with you"
You have probably been handed two unhelpful answers already. One is a shrug in an appointment that ran nine minutes and never got past your feet. The other is a confident voice online telling you diabetes killed your libido and here is the protocol that brings it back.
The research supports neither. Around half of women with diabetes score in the dysfunction range, the comparison against women without diabetes is real and carries a prediction interval that crosses zero, and the associated factors are depression, nerve damage, complications, duration and age. Most of that list has a clinician attached to it.
You have a diagnosis and a body that has been managing something demanding for years. Your desire has a context, and the relationship between the two is looser and more workable than anyone selling you a protocol wants to admit. If you have been quietly wondering whether you are broken: no. You are a woman with a metabolic condition, a medication list, and a life asking a lot of you. Any one of those flattens wanting. Low libido in women walks through the rest.
Keep reading
- Depression and low libido
- Blood pressure medication and sex drive
- Normal labs, low libido
- PCOS and low sex drive
- Why is my libido so low?
Frequently asked questions
Does diabetes affect sex drive?
Yes, and the pooled numbers are large. Across 50 studies covering 9,532 women with diabetes, 53% scored in the dysfunction range on a standard questionnaire (95% CI 46% to 61%). In that same analysis the factors most strongly associated with the score were depression (OR 2.781, 95% CI 2.012 to 3.844), diabetic neuropathy (OR 2.550, 95% CI 1.755 to 3.707) and diabetic complications (OR 2.258, 95% CI 1.346 to 3.788), with age and longer diabetes duration also raising the odds. Each of those is an association in cross-sectional data, so no direction of cause can be read off them. Take that list to your doctor.
Is it the diabetes or is it me?
It is most likely the things that travel with diabetes. In the largest pooled analysis the strongest association was depression, at odds of 2.781 (95% CI 2.012 to 3.844), followed by diabetic neuropathy at 2.550 and diabetic complications at 2.258. Type 1 reviews name depression and diabetes duration as the predictors that keep reappearing. Those are conditions with names and clinicians, and they are the reason a diagnosis is a context and a long way from a verdict. Nothing is wrong with you for having landed here.
My A1C is fine and I still feel nothing. Why?
Because blood sugar control was only ever a narrow part of this. The one review that looked directly, in 10 Indonesian studies of 572 women with type 2 diabetes, found HbA1c correlating with the desire section of the questionnaire alone. That review named being over 45 or menopausal and the use of antihypertensive medication as the other associations. Depression, diabetic neuropathy and diabetic complications carried the largest odds in the biggest pool, and sleep, medication and mood sit outside your A1C entirely.
Does type 1 diabetes lower libido too?
The reviews say the same thing for type 1 as for type 2. One pooled a prevalence of 38.5% (95% CI 32.1% to 45.0%) with odds against healthy controls of 3.77 (95% CI 2.24 to 6.35), and named depression (OR 2.77) and longer diabetes duration (OR 1.19) as predictors. A second pooled 18 studies of 2,476 women and got 37% (95% CI 30% to 43%), with an adjusted risk ratio against age-matched controls of 2.10 (95% CI 1.30 to 3.39), naming depression and diabetes-control indicators as the most consistent predictors. A third, in premenopausal women only, put the odds three times higher at 3.8 (95% CI 1.8 to 8.0) on eight studies, a wide interval on a small pool.
Does metformin lower sex drive?
No pooled study in this literature has measured metformin against desire in women, so anyone giving you a confident answer is inventing one. What these reviews do contain is a signal pointing at blood sugar control itself, where HbA1c correlated with the desire section of the questionnaire in one Indonesian review, and one drug-class association worth reviewing with a doctor, which was antihypertensive use in that same review. Bring your full medication list to your next appointment and change nothing on your own.
References
- Wang H, Zhao W, Jin S, et al. Prevalence and associated factors of sexual dysfunction in women with diabetes mellitus: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2026;23(5):qdag103. https://pubmed.ncbi.nlm.nih.gov/41999390/
- Tandogan O. Female Sexual Dysfunction Across Diabetes Types Compared to Non-Diabetic Controls: A Systematic Review and Meta-Analysis. Journal of Sex & Marital Therapy. 2026;52(6):608-622. https://pubmed.ncbi.nlm.nih.gov/42299862/
- Zhang X, Zhu Z, Tang G, Xu H. Prevalence and predictors of sexual dysfunction in females with type 1 diabetes: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2023;20(9):1161-1171. https://pubmed.ncbi.nlm.nih.gov/37548250/
- Banerjee M, Maisnam I, Mukhopadhyay P, Ghosh S. Female sexual dysfunction in type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2026;91(1):191. https://pubmed.ncbi.nlm.nih.gov/42209931/
- Hashim R, Forde R, Ausili D, Forbes A. Prevalence and associated factors of sexual dysfunction in premenopausal women with type 1 diabetes: A systematic review and meta-analysis. Diabetic Medicine. 2023;40(11):e15173. https://pubmed.ncbi.nlm.nih.gov/37403653/
- Pasaribu A, Astrella C, Kristanti M, et al. Prevalence and associated factors of female sexual dysfunction among type 2 diabetes patients in Indonesia: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome. 2023;17(11):102878. https://pubmed.ncbi.nlm.nih.gov/37898063/
- Maghalian M, Mirghafourvand M. Impact of gestational diabetes mellitus on women's sexual function: a systematic review and meta-analysis. BMC Endocrine Disorders. 2024;24(1):245. https://pubmed.ncbi.nlm.nih.gov/39543559/
- Vasquez-Tirado GA, Guarniz-Salavarria JD, Quispe-Castaneda CV, et al. Testosterone levels and risk of newly diagnosed type 2 diabetes mellitus in adult men: systematic review and meta-analysis. Endocrine. 2025;87(2):362-377. https://pubmed.ncbi.nlm.nih.gov/39251467/
This article is for general education and is not medical advice. Diabetes is a medical condition that only a licensed clinician can diagnose and manage. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing diabetes, neuropathy, depression, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not change any medication without your doctor.
